The alpha7-nicotinic receptor contributes to gp120-induced neurotoxicity: Implications in HIV-Associated neurocognitive Disorders

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Capó Vélez, Coral M ^a   Morales Vargas, Bryan ^a   García González, Aurian ^a   Grajales Reyes, José G ^a   Delgado Vélez, Manuel ^a   Madera, Bismark ^a   Báez Pagán, Carlos A ^a   Quesada, Orestes ^a   Lasalde Dominicci, José A ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN RECEPTOR; GLYCOPROTEIN GP 120; NICOTINIC RECEPTOR;

ANIMAL; C57BL MOUSE; CELL DEATH; CORPUS STRIATUM; DISORDERS OF HIGHER CEREBRAL FUNCTION; FEMALE; HIPPOCAMPUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MOUSE; NERVE CELL; PHYSIOLOGY; TOXICITY AND INTOXICATION; TRANSGENIC MOUSE;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; CELL DEATH; CORPUS STRIATUM; FEMALE; HIPPOCAMPUS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROCOGNITIVE DISORDERS; NEURONS; NEUROTOXICITY SYNDROMES; RECEPTORS, NICOTINIC;

EID: 85041232683     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-20271-x     Document Type: Article

References (67)

1. Ghafouri, M., Amini, S., Khalili, K. & Sawaya, B. E. HIV-1 associated dementia: symptoms and causes. Retrovirology 3, 28 (2006).
2. González-Scarano, F. & Martín-García, J. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5, 69-81 (2005).
3. Jaeger, L. B. & Nath, A. Modeling HIV-Associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis. Dis. Model. Mech. 5, 313-322 (2012).
4. Heaton, R. K. et al. HIV-Associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75, 2087-2096 (2010).
5. Njamnshi, A. K. et al. Risk factors for HIV-Associated neurocognitive disorders (HAND) in sub-Saharan Africa: The case of Yaoundé- Cameroon. J. Neurol. Sci. 285, 149-153 (2009).
6. Toggas, S. M. et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367, 188-193 (1994).
7. Persidsky, Y., Potula, R. & Haorah, J. Rodent model systems for studies of HIV-1 associated dementia. Neurotox. Res. 8, 91-106 (2005).
8. D'hooge, R., Franck, F., Mucke, L. & De Deyn, P. P. Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur. J. Neurosci. 11, 4398-4402 (1999).
9. Ballester, L. Y. et al. Up-regulation of the neuronal nicotinic receptor α7 by HIV glycoprotein 120: potential implications for HIVassociated neurocognitive disorder. J. Biol. Chem. 287, 3079-3086 (2012).
10. Delgado-Vélez, M. et al. The α7-nicotinic receptor is upregulated in immune cells from HIV-seropositive women: consequences to the cholinergic anti-inflammatory response. Clin. Transl. Immunol. 4, e53 (2015).
11. Ramos, F. M. et al. Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-Associated neurocognitive disorder. J. Neurovirol. https://doi.org/10.1007/s13365-015-0401-8(2015.
12. Von Giesen, H. J. et al. Basal ganglia metabolite abnormalities in minor motor disorders associated with human immunodeficiency virus type 1. Arch. Neurol. 58, 1281-1286 (2001).
13. Woods, S. P., Moore, D. J., Weber, E. & Grant, I. Cognitive neuropsychology of HIV-Associated neurocognitive disorders. Neuropsychol. Rev. 19, 152-168 (2009).
14. Jones, M. V., Bell, J. E. & Nath, A. Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS Lond. Engl. 14, 2709-2713 (2000).
15. Berger, J. R. & Nath, A. HIV dementia and the basal ganglia. Intervirology 40, 122-131 (1997).
16. Berger, J. R. & Arendt, G. HIV dementia: The role of the basal ganglia and dopaminergic systems. J. Psychopharmacol. Oxf. Engl. 14, 214-221 (2000).
17. Berger, J. R. et al. Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 54, 921-926 (2000).
18. Slemmer, J. E., Martin, B. R. & Damaj, M. I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295, 321-327 (2000).
19. Ward, J. M., Cockcroft, V. B., Lunt, G. G., Smillie, F. S. & Wonnacott, S. Methyllycaconitine: A selective probe for neuronal alphabungarotoxin binding sites. FEBS Lett. 270, 45-48 (1990).
20. Orr-Urtreger, A. et al. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J. Neurosci. Off. J. Soc. Neurosci. 17, 9165-9171 (1997).
21. Liu, Q. H. et al. HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc. Natl. Acad. Sci. USA 97, 4832-4837 (2000).
22. Séguéla, P., Wadiche, J., Dineley-Miller, K., Dani, J. A. & Patrick, J. W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: A nicotinic cation channel highly permeable to calcium. J. Neurosci. Off. J. Soc. Neurosci. 13, 596-604 (1993).
23. Marambaud, P., Dreses-Werringloer, U. & Vingtdeux, V. Calcium signaling in neurodegeneration. Mol. Neurodegener. 4, 20 (2009).
24. Maravall, M., Mainen, Z. F., Sabatini, B. L. & Svoboda, K. Estimating intracellular calcium concentrations and buffering without wavelength ratioing. Biophys. J. 78, 2655-2667 (2000).
25. Mansvelder, H. D., Mertz, M. & Role, L. W. Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin. Cell Dev. Biol. 20, 432-440 (2009).
26. Paterson, D. & Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61, 75-111 (2000).
27. Kaul, M., Garden, G. A. & Lipton, S. A. Pathways to neuronal injury and apoptosis in HIV-Associated dementia. Nature 410, 988-994 (2001).
28. Cao, J. et al. RNA deep sequencing analysis reveals that nicotine restores impaired gene expression by viral proteins in the brains of HIV-1 transgenic rats. PloS One 8, e68517 (2013).
29. Mair, R. G., Koch, J. K., Newman, J. B., Howard, J. R. & Burk, J. A. A double dissociation within striatum between serial reaction time and radial maze delayed nonmatching performance in rats. J. Neurosci. Off. J. Soc. Neurosci. 22, 6756-6765 (2002).
30. Lim, S. A. O., Kang, U. J. & McGehee, D. S. Striatal cholinergic interneuron regulation and circuit effects. Front. Synaptic Neurosci. 6, 22 (2014).
31. Grajales-Reyes, G. E. et al. Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions. Pharmacogenomics J. 13, 362-368 (2013).
32. Grajales-Reyes, J. G. et al. A Panel of Slow-Channel Congenital Myasthenic Syndrome Mice Reveals a Unique Locomotor BehavioralSignature. J. Neuromuscul. Dis. https://doi.org/10.3233/JND-170226 (2017).
33. Pedrol-Clotet, E. et al. Bupropion use for smoking cessation in HIV-infected patients receiving antiretroviral therapy. Enfermedades Infecc. Microbiol. Clínica 24, 509-511 (2006).
34. Currier, M. B., Molina, G. & Kato, M. A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics 44, 120-125 (2003).
35. Eller, T., Vasar, V., Shlik, J. & Maron, E. Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J. Psychopharmacol. Oxf. Engl. 23, 854-858 (2009).
36. Kovalevich, J. & Langford, D. Neuronal toxicity in HIV CNS disease. Future Virol. 7, 687-698 (2012).
37. Azam, L., Winzer-Serhan, U. & Leslie, F. M. Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. Neuroscience 119, 965-977 (2003).
38. Bonsi, P. et al. Centrality of striatal cholinergic transmission in Basal Ganglia function. Front. Neuroanat. 5, 6 (2011).
39. Catani, M. V. et al. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors. J. Neurochem. 74, 2373-2379 (2000).
40. Hesselgesser, J. et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr. Biol. CB 8, 595-598 (1998).
41. Zhang, J., Liu, J., Katafiasz, B., Fox, H. & Xiong, H. HIV-1 gp120-induced axonal injury detected by accumulation of β-Amyloid precursor protein in adult rat corpus callosum. J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 6, 650-657 (2011).
42. Adamson, D. C., Kopnisky, K. L., Dawson, T. M. & Dawson, V. L. Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity. J. Neurosci. Off. J. Soc. Neurosci. 19, 64-71 (1999).
43. Bagashev, A. & Sawaya, B. E. Roles and functions of HIV-1 Tat protein in the CNS: An overview. Virol. J. 10, 358 (2013).
44. Saito, Y. et al. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44, 474-481 (1994).
45. Mattson, M. P., Haughey, N. J. & Nath, A. Cell death in HIV dementia. Cell Death Differ. 12(Suppl 1), 893-904 (2005).
46. Liu, L. et al. Alpha7 nicotinic acetylcholine receptor is required for amyloid pathology in brain endothelial cells induced by Glycoprotein 120, methamphetamine and nicotine. Sci. Rep. 7, 40467 (2017).
47. Deeks, S. G., Tracy, R. & Douek, D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39, 633-645 (2013).
48. Hearps, A. C., Martin, G. E., Rajasuriar, R. & Crowe, S. M. Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr. HIV/AIDS Rep. 11, 20-34 (2014).
49. Rao, V. R., Ruiz, A. P. & Prasad, V. R. Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res. Ther. 11, 13 (2014).
50. Wang, H. et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421, 384-388 (2003).
51. Shytle, R. D. et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89, 337-343 (2004).
52. Jonnala, R. R. & Buccafusco, J. J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res. 66, 565-572 (2001).
53. Guerra-Álvarez, M. et al. Positive allosteric modulation of alpha-7 nicotinic receptors promotes cell death by inducing Ca(2+) release from the endoplasmic reticulum. J. Neurochem. 133, 309-319 (2015).
54. Heaton, R. K. et al. HIV-Associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17, 3-16 (2011).
55. Navia, B. A., Jordan, B. D. & Price, R. W. The AIDS dementia complex: I. Clinical features. Ann Neurol 19, 517-524 (1986).
56. Ouchi, Y. et al. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: A positron emission tomography study. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 22, 746-752 (2002).
57. Rowland, T. W. The biological basis of physical activity. Med. Sci. Sports Exerc. 30, 392-399 (1998).
58. Sherwin, null. Voluntary wheel running: A review and novel interpretation. Anim. Behav. 56, 11-27 (1998).
59. Swallow, J. G., Carter, P. A. & Garland, T. Artificial selection for increased wheel-running behavior in house mice. Behav. Genet. 28, 227-237 (1998).
60. Sidhpura, N., Redfern, P., Rowley, H., Heal, D. & Wonnacott, S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem. Pharmacol. 74, 1292-1298 (2007).
61. Kaiser, S. & Wonnacott, S. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58, 312-318 (2000).
62. Wonnacott, S., Kaiser, S., Mogg, A., Soliakov, L. & Jones, I. W. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol. 393, 51-58 (2000).
63. Brewer, G. J. & Torricelli, J. R. Isolation and culture of adult neurons and neurospheres. Nat. Protoc. 2, 1490-1498 (2007).
64. Paxinos, G. & Franklin, K. The Mouse Brain in Stereotaxic Coordinates, (Academic Press, 2008).
65. Haugland, P. D. R. P. The Handbook: A Guide to Fluorescent Probes and Labeling Technologies. (Invitrogen Corp., 2005).
66. Chilton, M., Mastropaolo, J., Rosse, R. B., Bellack, A. S. & Deutsch, S. I. Behavioral consequences of methyllycaconitine in mice: A model of alpha7 nicotinic acetylcholine receptor deficiency. Life Sci. 74, 3133-3139 (2004).
67. Suckow, R. F., Smith, T. M., Perumal, A. S. & Cooper, T. B. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab. Dispos. Biol. Fate Chem. 14, 692-697 (1986).